Browse > Article

Development of shielding device for bremsstrahlung radiation from Y-90 microspheres  

Park, Jun Young (Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine)
Publication Information
The Korean Journal of Nuclear Medicine Technology / v.23, no.1, 2019 , pp. 50-53 More about this Journal
Abstract
Purpose Yttrium-90 (Y-90) is high-energy beta emitters ($E{\beta}$, max = 2.28 MeV) with the mean penetration depth of 2.5 mm in tissue. Radioactive microspheres containing Y-90 is widely used for the transarterial radioembolization of hepatocellular carcinoma. However, bremsstrahlung radiation from Y-90 can cause the external radiation exposure to medical staff who handle the Y-90 microspheres. In this study, shielding device for Y-90 microspheres was developed to minimize the external radiation exposure. Materials and Methods Y-90 microsphere shielding device was made from 6 mm thicknesses of tungsten including the lead glass window. Radiation shielding ability of Y-90 microsphere shielding device was evaluated using 4 GBq of $SIR-Spheres^{(R)}$ Y-90 microspheres. The bremsstrahlung radiation was measured using radiation survey meter. Results The mean radiation dose of Y-90 microspheres in acrylic shield was $261.7{\pm}2.3{\mu}Sv/h$ (n=5) at 10 cm away from the shield. With the additional tungsten shielding device, it was $23.7{\pm}1.3{\mu}Sv/h$ (n=5). Thus, the bremsstrahlung radiation dose was decreased by 90.9%. At 50 cm away from the shield, bremsstrahlung radiation was reduced by 89.2% after using tungsten shielding device. Conclusion During the preparation and radioembolization of Y-90 microsphere, medical staff are exposed to external radiation. In this study, we demonstrated that the use of tungsten shielding device devices significantly reduced the amount of bremsstrahlung radiation. Y-90 microsphere tungsten shielding device can be highly effective in reducing the bremsstrahlung radiation.
Keywords
Y-90; Radiotherapy; Bremsstrahlung; Radiation shield; Radiation exposure;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Chung JW. Recent advance in international management of hepatocellular carcinoma. J Korean Med Assoc. 2013;56:972-982   DOI
2 Kassis AI. Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med. 2008; 38:358-366   DOI
3 Boyle DA. Hepatocellular carcinoma: implications for asia-pacific oncology nurses. Asia Pac J Oncol Nurs. 2017;4:98-103   DOI
4 통계청. 2017 사망원인통계. 온라인 간행물; 2018. p.1-55
5 보건복지부, 신의료기술평가위원회. 동맥경유 방사선색전술의 신의료기술평가보고서. 온라인 간행물; 2010. p.1-180
6 Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018   DOI
7 Korean Liver Cancer Study Group. 2014 Korean liver cancer study group-national cancer center korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol. 2015; 16:465-522   DOI
8 대한간암학회, 국립암센터. 2018 간세포암종 진료 가이드라인. 온라인 간행물; 2018. p.1-169
9 Bouvry C, Palard X, Edeline J, Ardisson V, Loyer P, Garin E, et al. Transarterial Radioembolization (TARE) Agents beyond $^{90}Y$-Microspheres. Biomed Res Int. 2018; 2018:1435302   DOI